Preview 8 late-breaking studies and HCPLive's investigator interviews at ASN Kidney Week 2026, spanning IgAN, dialysis, transplantation, and CKD.

Todd Schlesinger, MD, discusses Ameluz PDT for sBCC, adjuvant cemiplimab, remibrutinib for symptomatic dermographism, and nonsurgical skin cancer care.

In an interim extension analysis presented at NACFC 2026, 37.5% of young children with CF in a PERT substudy stopped enzyme therapy on the regimen.

Day 2 highlights from Phoenix covering PE intervention trials, pulmonary hypertension diagnostics, ILD telomere biology, and more.

In 503 patients with ILD, telomere length below the 10th percentile was linked to UIP pattern on CT and higher MIL-UIP scores but not greater fibrosis extent.

Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.

Clinicians described how steroid exposure from multiple prescribers shapes biologic decisions in asthma and COPD.

From oral IL-23 blockade in UC to sex-specific FIT thresholds and a swallowable Barrett’s test, these are 7 trials from ACG 2026 clinicians should know.